Group 1: New Housing Market - The new housing market in Beijing has shown signs of stability, with a total transaction area of 2.67 million square meters in the first half of the year, reflecting a year-on-year increase of 3% [2] - Six new housing projects achieved sales exceeding 4 billion yuan, indicating a strong performance in high-quality improvement properties [2][3] - The high-end segment of the new housing market has seen significant growth, with transactions for properties priced between 10 million to 20 million yuan increasing by nearly 90% year-on-year, raising its market share from 12% in 2024 to approximately 19% [3] Group 2: Land Supply and Transactions - In the first half of the year, Beijing completed 22 residential land transactions, with a total transaction value of 100.56 billion yuan, a year-on-year increase of 37.3% [4] - The land auction market has shown a trend of "volume shrinking but price rising," with several core and high-value plots being sold, indicating strong demand despite reduced supply [4] Group 3: Second-hand Housing Market - The second-hand housing market in Beijing has seen a significant increase, with a total of 88,575 transactions in the first half of the year, representing an 18% year-on-year growth [6] - The majority of buyers in the second-hand market are first-time homebuyers, with over 60% of transactions being for properties priced below 5 million yuan [6][5] - The second-hand market is characterized by a "price for volume" approach, with average prices showing slight declines due to high inventory levels [7] Group 4: Market Outlook - The current reasonable price levels in the second-hand market are expected to maintain stable transaction volumes, with suggestions for policy adjustments to control new housing supply and enhance support for homebuyers [8]

PRAME Franchise & Market Opportunity - Immatics is developing three clinical product candidates (IMA402, IMA203, IMA203CD8) precisely targeting PRAME, an intracellular protein presented on tumor cell surfaces[10, 12] - PRAME expression is prevalent in over 50 cancers[8], with prevalence ranging from 20% in Hepatocellular Carcinoma and Bladder Carcinoma to 95% in Cutaneous Melanoma, Uterine Carcinoma, and Synovial Sarcoma[9] - The addressable PRAME+/HLA-A*02:01+ patient population in the US & EU5 is estimated to be approximately 230,000 per year[20, 24] IMA203 PRAME Cell Therapy (Wave 1) - In a Phase 1 study, IMA203 demonstrated a confirmed objective response rate (cORR) of 56% (18/32) in heavily pretreated patients with metastatic melanoma[34, 45] - The median duration of response (mDOR) was 121 months, with ongoing responses for up to 25+ years[34] - The median progression-free survival (mPFS) was 61 months, and the median overall survival (mOS) was 159 months in all melanoma patients[34, 51] - The SUPRAME Phase 3 trial is actively enrolling patients with unresectable or metastatic melanoma post-ICI, with a planned launch in Q3 2027[35, 59] - Approximately 9,000 PRAME+/HLA-A*02:01+ patients in the US/EU5 with cutaneous and uveal melanoma are addressable[34] IMA203CD8 PRAME Cell Therapy (GEN2) (Wave 2) - IMA203CD8 is a next-generation PRAME cell therapy leveraging CD8 and CD4 T cells, with enhanced pharmacology[24] - In a Phase 1a dose escalation study, IMA203CD8 achieved a cORR of 41% (14/34) at presumably suboptimal doses, with 84% (32/38) of patients experiencing tumor shrinkage[73, 85] - The median duration of response (mDOR) was 92 months, with 3 confirmed responses ongoing at 1+ year[73, 85] - The addressable PRAME+/HLA-A*02:01+ patient opportunity for IMA203CD8 is approximately 75,000 per year, including indications with both high and medium-level PRAME expression[20, 68] IMA402 PRAME Bispecific (Wave 3) - IMA402 is a next-generation half-life extended bispecific primarily targeting first-line settings in combination with ICI and targeted agents[22] - Early signs of clinical activity have been observed, with a melanoma patient achieving a confirmed partial response ongoing at 3 months at DL7[115] - The addressable PRAME+/HLA-A*02:01+ patient population for IMA402 in 1L solid tumors is approximately 145,000 in the US & EU5[20, 100] Beyond PRAME: IMA401 MAGEA4/8 Bispecific - IMA401 is a bispecific targeting MAGEA4/8, with a Phase 1a study demonstrating a 29% (5/17) ORR and 25% (4/16) cORR in patients with MAGEA4/8high expression at relevant doses[132, 149] - The addressable MAGEA4/8+ and HLA-A*02:01+ patient population in the US & EU5 is approximately 62,000 per year[128, 130]

Business Overview - U.S net product revenue of NEXLETOL® and NEXLIZET® grew by 12% from Q3 2021 to $12.2 million in Q4 2021[10] - Sequential prescription growth of 9% from Q3 2021 with over 70,000 cumulative patients[10] - CLEAR Outcomes trial reached 90% MACE Accumulation in February 2022, with topline results expected in Q1 2023[10, 16] Financial Update - Ended Q4 2021 with $309.3 million in cash, cash equivalents, restricted cash and investment securities[10] - FY 2021 Operating Expenses were $305 million[22] - FY 2022 R&D Guidance is $100 - $110 million[22] - FY 2022 SG&A Guidance is $120 - $130 million[22] - Future Ex-U.S Collaboration Milestones from Daiichi Sankyo & Otsuka are >$1.2 billion[22] - Q4 2021 Common Shares Outstanding were 60.9 million[22]

Business Highlights - Approximately 35 million patients are considered statin intolerant in the U S, Japan, and the EU[8] - Statin intolerance impacts up to 20% of individuals treated with a statin[8, 12] - CLEAR Outcomes trial has enrolled over 14,000 patients and is powered for success[12] - The CLEAR Outcomes trial expects a high baseline LDL-C of approximately 140 mg/dL[12] Operational Performance - Over 8,600 doctors are writing at least one prescription for Esperion's medicines[15] - More than 3,300 patients are taking Esperion's medicines every week[15] - Over 420,000 seven-day starter packs have been requested and received[15] - New-to-brand statin prescriptions are down 9% year-to-date 2021 compared to year-to-date 2020 due to COVID-19 impacts[17] Financial Results & Guidance - U S Net Product Sales increased 14 6% quarter over quarter[23] - Royalty revenues from DSE were $8 2 million in the quarter[23] - Ex-U S Collaboration Milestones were $3 3 million[23] - The company anticipates FY 2021 revenues between $120 - $130 million[26]

FORWARD-LOOKNG STATEMENTS & DISCLOSURES MAY 3, 2022 © 2022 Esperion. All Rights Reserved – For investor audience only WHEN DO YOU PLAN TO GET YOUR NEXT CHOLESTEROL TEST? This presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization plans, current and planned operational expenses, future operations, commercial products, clinical development, including the timing ...

Core Insights - The Tocotrienol Market is expected to grow from USD 380.60 million in 2025 to USD 528.59 million by 2030, representing a CAGR of 6.79% driven by increasing consumer awareness of health and wellness [2] - The demand for tocotrienols is rising in both dietary supplements and cosmetics due to their health benefits and antioxidant properties [3][5] Market Dynamics - The growth of the tocotrienol market is fueled by heightened awareness of its health benefits, particularly in disease management, and the increasing demand for anti-aging products [5][7] - Key players in the market are investing in R&D to innovate and differentiate their product offerings, with a focus on natural and functional ingredients [3][4] Regional Insights - The Asia-Pacific region, especially China, is a leading market for tocotrienols, supported by a growing focus on functional foods and nutritional supplements [6] - Japan's aging population, where 29% are over 60, is contributing to the demand for tocotrienols due to their health benefits [6] Competitive Landscape - Major players in the tocotrienol market include BASF SE, Fuji Chemical Industries Co. Ltd, and ExcelVite Sdn. Bhd., who are expanding production capabilities while adhering to safety standards [4][8] - The market is characterized by competitive dynamics, with companies adopting various strategies to enhance their market positioning [8]

【环球网科技综合报道】7月3日消息，据外媒9to5mac报道称， 2025 年已过半，苹果在产品创新上持续发力，计划于今年秋季推出超 15 款新产品。 外媒称，此次苹果可穿戴设备将迎强劲更新，Apple Watch Ultra 3 将配备 5G RedCap、高血压传感器和卫星功能，Apple Watch Series 11 和 SE 3 也将升级； AirPods Pro 3 将搭载 H3 处理器并升级降噪功能。 据介绍，苹果将推出至少两款智能家居新品，包括新款 Apple TV 4K（配备 A 级芯片和 Apple Intelligence 功能）、HomePod mini 2（搭载全新 Wi-Fi 调制解 调器）以及可能的 "HomePad" 智能家居指挥中心。 苹果还将发布 AirTag 2（配备新型超宽带芯片）、M5 Vision Pro（规格提升）和 Studio Display 2（采用 MiniLED 技术并改进摄像头）。此外，有传言称苹 果可能推出 Pro Display XDR 2，以搭配新款 Mac Pro。（青云） 其中，苹果将推出 iPhone 17 系列，包括 iPhone 17、 ...

作为大模型领域的年度风向标，论坛每年吸引超3000多人报名、100家主流媒体报道，覆盖面超200000 人次。历届成果被央视、新华社、智通财经等媒体广泛报道，相关话题全网阅读量突破3百万次，更推 动超30家企业加速布局大模型应用，促成多项技术合作项目落地。 中国信通院作为权威智库机构，在大模型技术探索与应用方面始终处于领先地位，并取得了丰硕成果。 华东分院已连续七年支撑WAIC核心论坛，见证并推动了人工智能从基础研究到实际应用的每一步发 展，此次论坛是我院落实国家人工智能发展战略、抢占全球技术制高点的关键举措，将统筹全院科研力 量，整合多部门资源，打造大模型技术攻关与产业赋能的"国家队"。 本次论坛将汇聚全球顶尖外籍嘉宾、学者、行业领袖、AI领域权威专家将带来前沿洞察，头部企业代 表将深度解析大模型技术的突破性进展与产业落地实践，形成"政产学研用"多方智慧交融的顶级对话平 台，为全球大模型发展提供中国方案。 论坛期间将集中发布多项前沿研究成果，涵盖"人工智能+"融合应用、终端智能体安全、垂直领域大模 型创新实践等多个关键方向。这些重磅成果将为大模型在垂直行业的规模化落地提供可复制、可推广的 解决方案。 202 ...

WHEN DO YOU PLAN TO GET YOUR NEXT CHOLESTEROL TEST? FORWARD-LOOKNG STATEMENTS & DISCLOSURES This presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization plans, restructuring and current and planned operational expenses, future operations, commercial products, clinical development including the timing, designs and plans for the CLEAR Outcomes study and its resu ...

会议指出，2024年按照全省打击传销工作总体部署，各成员单位按照工作职责，认真落实任务分工，强 化协同配合，加强执法协作，深入宣传教育，打击传销工作组织领导不断强化、工作合力持续增强、社 会氛围日益浓厚，全社会抵制传销意识明显增强，群众识别、防范传销的能力显著提高。 中国质量新闻网讯 为进一步落实打击和防范传销工作任务，依法严惩传销违法犯罪行为，切实维护市 场经济秩序和人民群众根本利益，近日，青海省海北州市场监管局组织召开打击传销工作联席会议。 会议要求，各成员单位要按照联席会议确定的工作职责，落实任务分工，扎实推进打击传销工作。一要 高站位谋划，一以贯之夯实打击传销思想基础。进一步提高对开展打击传销工作重要性的认识，加强源 头治理和事先防范，真正把不稳定隐患消除在萌芽状态。二要强化协作，高效治理，筑牢民生安全防 线。发挥各部门协调联动机制作用，进一步增强执法协作力度，坚持问题导向，逐级压实责任。三要强 化监管，推动打传规直工作长效化。以执法办案为导向，持续对传销活动保持高压严打态势，确保措施 到位、见到实效。四要高力度宣教，一贯到底织密社会防控网络。把打击传销宣传教育工作作为从源头 上防范和抵制传销、维护社 ...